• Corpus ID: 18681689

The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects.

  title={The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects.},
  author={I R Dinu and Simona Popa and Mihaela L. B{\^i}cu and Eugen Moța and Maria Moța},
  journal={Romanian journal of internal medicine = Revue roumaine de medecine interne},
  volume={47 1},
  • I. Dinu, S. Popa, M. Moța
  • Published 2009
  • Biology, Psychology
  • Romanian journal of internal medicine = Revue roumaine de medecine interne
The endocannabinoid system (ECS) represents one of the most important physiologic systems involved in organism homeostasis, having various implications upon individual behavior and metabolic phenotype. It is composed of cannabinoid receptors CB1 and CB2, and their genes (CNR1 and CNR2), their endogenous ligands and the enzymes which mediate endogenous ligands' biosynthesis and degradation. Anandamide and 2-arachidonoylglycerol are two endogenous agonists of the cannabinoid receptors. It is… 

Figures and Tables from this paper

The association of the rs1049353 polymorphism of the CNR1 gene with hypoadiponectinemia.
  • I. Dinu, S. Popa, M. Cruce
  • Biology
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • 2011
It is indicated that the rs1049353 polymorphism of the CNR1 gene is associated with decreased levels of adiponectin, and further research is needed in order to elucidate the link between the polymorphisms of theC NR1 gene and adiponECTin levels.
What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?
The role of the ECS and the impact of genetic factors on endocannabinoid system modulation in the pathogenesis of obesity is explained and the search for potential new targets for health assessment, treatment, and the development of possible therapies in obesity is emphasized.
The association of the rs 1049353 polymorphism of the CNR 1 gene with hypoadiponectinemia
It is indicated that the rs1049353 polymorphism of the CNR1 gene is associated with decreased levels of adiponectin, an important physiological system that modulates appetite, food intake, energy homeostasis, substance addiction.
Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features
The studies provided the first evidence for neuronal CNS effects of CB2Rs and their possible role in drug addiction, eating disorders, psychosis, depression and autism spectrum disorders (ASDs) and where possible in rodent models have been assessed.
Dissecting the cannabinergic control of behavior: The where matters
Understanding the cellular and subcellular function of CB1R will provide new insights and aid the design of new compounds in cannabinoid‐based medicine.
Endocannabinoids and Schizophrenia
Levels of anandamide and 2-arachydonoylglycerol are increased in the cerebrospinal fluid (CSF) and in the serum of schizophrenia patients, suggesting that they may play a protective role in psychosis homeostasis.
Allele-specific Differences in Activity of a Novel Cannabinoid Receptor 1 (CNR1) Gene Intronic Enhancer in Hypothalamus, Dorsal Root Ganglia, and Hippocampus*
Alleles of enhancer may be functionally linked to obesity and addictive behavior and further analysis of the different alleles of ECR1 may lead to a greater understanding of the role of CNR1 gene misregulation in these conditions as well as chronic inflammatory pain.
Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk
CB1R (periphero-)neutral antagonists merit continued analysis of their molecular pharmacology and evaluation of their therapeutic significance and translational potential as new-generation medicines for obesity-related derangements, including nonalcoholic fatty liver disease and type 2 diabetes, if not obesity itself.
Cannabinoid Receptor Gene Variations in Drug Addiction and Neuropsychiatric Disorders
Novel human and rodent CB2R isoforms with differential tissue expression patterns and regulation by CBR ligands are identified and may provide a deeper insight and novel targets for the effects of cannabinoids in drug addiction and other neuropsychiatric disorders.


The role of the endocannabinoid system in the regulation of energy homeostasis
Developing ligands for endocannabinoid receptors is an important novel therapeutic strategy for the treatment of metabolic dysregulation and evidence is growing that activity of the endoc cannabinoidoid system is increased in animal and human obesity.
The emerging role of the endocannabinoid system in endocrine regulation and energy balance.
The ability of the endocannabinoid system to control appetite, food intake, and energy balance has recently received great attention, particularly in the light of the different modes of action underlying these functions.
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
A comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy is provided.
Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders.
Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men.
Genetic variants at CNR1 are associated with obesity-related phenotypes in men and the detection of polymorphic variants in genes involved in the process of fat accumulation may help identify specific targets for pharmacological treatment of obesity and related metabolic abnormalities.
The endocannabinoid system: a general view and latest additions
The latest ‘additions’ to the endocannabinoid system are reviewed together with earlier breakthroughs that have contributed to the present knowledge of the biochemistry and pharmacology of theendocannabinoids.
The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract
An alternative and promising avenue for therapeutic applications resides in the treatment with CB1 receptor agonists that are unable to cross the blood–brain barrier, or with compounds that inhibit the degradation of endogenous ligands (endocannabinoids) of CB1 receptors, hence prolonging the activity of the endocannabinoid system.
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.
It is shown that the lack of CB1 in mice with a disrupted CB1 gene causes hypophagia and leanness, and the cannabinoid system is an essential endogenous regulator of energy homeostasis via central orexigenic as well as peripheral lipogenic mechanisms and might therefore represent a promising target to treat diseases characterized by impaired energy balance.
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.
It is concluded that anandamide acting at hepatic CB(1) contributes to diet-induced obesity and that the FAS pathway may be a common molecular target for central appetitive and peripheral metabolic regulation.
The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men
The data indicate that the G1422A polymorphism in the CNR1 gene is associated with increased abdominal adiposity in obese men.